Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Ovarian Neoplasms 12Breast Neoplasms 9Fallopian Tube Neoplasms 6Carcinoma, Ovarian Epithelial 5Squamous Cell Carcinoma of Head and Neck 4Endometrial Neoplasms 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Non Small Cell Lung Carcinoma NSCLC 2Neoplasms, Unknown Primary 2Neoplasms 2NSCLC 2Melanoma 2Esophageal Neoplasms 2Adenocarcinoma 2Urologic Neoplasms 1Urogenital Neoplasms 1Unresectable Stage III NSCLC 1Triple Negative Metastatic Breast Cancer 1Thyroid Neoplasms 1Thrombocytopenia 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcopenia 1

Interventions

Cisplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-Small Cell Lung Cancer With HER2- Mutations × CP protocol × Clear all
NCT06430437 2026-01-21

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
300 enrolled
Thoracic

Non-Small Cell Lung Cancer With HER2- Mutations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡